-The Hindu Business Line Industry likely to meet officials today New Delhi: Patients with debilitating knee problems, requiring joint replacement surgeries, would soon regain spring in their steps. The National Pharmaceutical Pricing Authority (NPPA), which capped the prices of coronary stents in February, may cap the prices of knee implants soon. According to a source in the know of the developments, the price of knee implants is likely to be capped with just...

-The Indian Express Responding to specific queries on the issue, Bhupendra Singh, NPPA chairman, told The Indian Express that “examination of hospital records is in process”. AFTER the National Pharmaceutical Pricing Authority (NPPA) in February ordered a cap on the prices of coronary stents and directed hospitals to issue separate bills specifying their cost, the drug pricing watchdog has started receiving consumer complaints against hospitals which are allegedly hiking the prices...

-The Times of India Multinational stent companies claim that the ceiling price fixed by the National Pharmaceutical Pricing Authority (NPPA) is commercially unviable, but they are selling at far lower prices in much richer countries with smaller markets than India such as Germany, the UK, Italy and many other European countries. A look at the prices of stent brands in these countries shows that people in India have been defrauded of crores...

-The Telegraph New Delhi: The government's price cap on coronary stents has not deterred the health-care industry from continuing to offer hospitals profit opportunities of tens of thousands of rupees on other kinds of stents, concerned doctors and health-care industry representatives said.     The National Pharmaceutical Pricing Authority (NPPA), the government's price regulator, had on February 15 imposed a cap of about Rs 30,000 on coronary stents. But hospitals can continue to...

-The Times of India NEW DELHI: The government has invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months. Amid reports that several manufacturers, including Abbott and Medtronic, are seeking to withdraw premium, high-priced stents from the Indian market on account of the price cap imposed by National Pharmaceutical Pricing Authority (NPPA), the government has directed companies to maintain production,...